ID   AHDC1_HUMAN             Reviewed;        1603 AA.
AC   Q5TGY3; Q5TGY4; Q6PJK1; Q6ZUQ6; Q99769; Q9NUF5;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   21-DEC-2004, sequence version 1.
DT   28-JUN-2023, entry version 139.
DE   RecName: Full=Transcription factor Gibbin {ECO:0000303|PubMed:35585237};
DE   AltName: Full=AT-hook DNA-binding motif-containing protein 1 {ECO:0000305};
GN   Name=AHDC1 {ECO:0000303|PubMed:24791903, ECO:0000312|HGNC:HGNC:25230};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 818-1603, AND VARIANT THR-935.
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1126-1603.
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1137-1603.
RC   TISSUE=Brain;
RX   PubMed=9110174; DOI=10.1101/gr.7.4.353;
RA   Yu W., Andersson B., Worley K.C., Muzny D.M., Ding Y., Liu W.,
RA   Ricafrente J.Y., Wentland M.A., Lennon G., Gibbs R.A.;
RT   "Large-scale concatenation cDNA sequencing.";
RL   Genome Res. 7:353-358(1997).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1399, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-829, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-846 AND SER-1399, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-596, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-596; SER-896; SER-1064;
RP   SER-1187; SER-1399 AND SER-1507, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   INVOLVEMENT IN XIGIS.
RX   PubMed=24791903; DOI=10.1016/j.ajhg.2014.04.006;
RA   Xia F., Bainbridge M.N., Tan T.Y., Wangler M.F., Scheuerle A.E.,
RA   Zackai E.H., Harr M.H., Sutton V.R., Nalam R.L., Zhu W., Nash M.,
RA   Ryan M.M., Yaplito-Lee J., Hunter J.V., Deardorff M.A., Penney S.J.,
RA   Beaudet A.L., Plon S.E., Boerwinkle E.A., Lupski J.R., Eng C.M.,
RA   Muzny D.M., Yang Y., Gibbs R.A.;
RT   "De novo truncating mutations in AHDC1 in individuals with syndromic
RT   expressive language delay, hypotonia, and sleep apnea.";
RL   Am. J. Hum. Genet. 94:784-789(2014).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-268; SER-1399 AND SER-1507,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-891, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [15]
RP   INVOLVEMENT IN XIGIS.
RX   PubMed=29230160; DOI=10.1159/000479357;
RA   Garcia-Acero M., Acosta J.;
RT   "Whole-exome sequencing identifies a de novo AHDC1 mutation in a colombian
RT   patient with Xia-Gibbs syndrome.";
RL   Mol. Syndromol. 8:308-312(2017).
RN   [16]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-609 AND LYS-1409, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [17]
RP   INVOLVEMENT IN XIGIS.
RX   PubMed=31182893;
RA   Diaz-Ordonez L., Ramirez-Montano D., Candelo E., Cruz S., Pachajoa H.;
RT   "Syndromic Intellectual Disability Caused by a Novel Truncating Variant in
RT   AHDC1: A Case Report.";
RL   Iran. J. Med. Sci. 44:257-261(2019).
RN   [18]
RP   VARIANT XIGIS 494-LYS--LEU-1603 DEL.
RX   PubMed=27148574; DOI=10.1101/mcs.a000562;
RA   Yang H., Douglas G., Monaghan K.G., Retterer K., Cho M.T., Escobar L.F.,
RA   Tucker M.E., Stoler J., Rodan L.H., Stein D., Marks W., Enns G.M.,
RA   Platt J., Cox R., Wheeler P.G., Crain C., Calhoun A., Tryon R., Richard G.,
RA   Vitazka P., Chung W.K.;
RT   "De novo truncating variants in the AHDC1 gene encoding the AT-hook DNA-
RT   binding motif-containing protein 1 are associated with intellectual
RT   disability and developmental delay.";
RL   Cold Spring Harb. Mol. Case Stud. 1:a000562-a000562(2015).
RN   [19]
RP   VARIANTS XIGIS 262-GLN--LEU-1603 DEL; 688-ARG--LEU-1603 DEL;
RP   882-GLN--LEU-1603 DEL; 925-ARG--LEU-1603 DEL; 970-GLN--LEU-1603 DEL;
RP   1258-SER--LEU-1603 DEL AND 1330-SER--LEU-1603 DEL.
RX   PubMed=29696776; DOI=10.1002/ajmg.a.38699;
RA   Jiang Y., Wangler M.F., McGuire A.L., Lupski J.R., Posey J.E., Khayat M.M.,
RA   Murdock D.R., Sanchez-Pulido L., Ponting C.P., Xia F., Hunter J.V.,
RA   Meng Q., Murugan M., Gibbs R.A.;
RT   "The phenotypic spectrum of Xia-Gibbs syndrome.";
RL   Am. J. Med. Genet. A 176:1315-1326(2018).
RN   [20]
RP   VARIANTS XIGIS 494-LYS--LEU-1603 DEL; 587-ARG--LEU-1603 DEL AND
RP   825-GLN--LEU-1603 DEL.
RX   PubMed=30152016; DOI=10.1002/ajmg.a.40380;
RA   Ritter A.L., McDougall C., Skraban C., Medne L., Bedoukian E.C.,
RA   Asher S.B., Balciuniene J., Campbell C.D., Baker S.W., Denenberg E.H.,
RA   Mazzola S., Fiordaliso S.K., Krantz I.D., Kaplan P., Ierardi-Curto L.,
RA   Santani A.B., Zackai E.H., Izumi K.;
RT   "Variable clinical manifestations of Xia-Gibbs syndrome: findings of
RT   consecutively identified cases at a single children's hospital.";
RL   Am. J. Med. Genet. A 176:1890-1896(2018).
RN   [21]
RP   VARIANT XIGIS 327-GLN--LEU-1603 DEL.
RX   PubMed=30622101; DOI=10.1101/mcs.a003608;
RA   Murdock D.R., Jiang Y., Wangler M., Khayat M.M., Sabo A., Juusola J.,
RA   McWalter K., Schatz K.S., Gunay-Aygun M., Gibbs R.A.;
RT   "Xia-Gibbs syndrome in adulthood: a case report with insight into the
RT   natural history of the condition.";
RL   Cold Spring Harb. Mol. Case Stud. 5:0-0(2019).
RN   [22]
RP   INVOLVEMENT IN XIGIS.
RX   PubMed=30729726; DOI=10.1002/mgg3.596;
RA   Cheng X., Tang F., Hu X., Li H., Li M., Fu Y., Yan L., Li Z., Gou P.,
RA   Su N., Gong C., He W., Xiang R., Bu D., Shen Y.;
RT   "Two Chinese Xia-Gibbs syndrome patients with partial growth hormone
RT   deficiency.";
RL   Mol. Genet. Genomic Med. 7:e00596-e00596(2019).
RN   [23]
RP   VARIANT XIGIS GLY-1457.
RX   PubMed=30858058; DOI=10.1016/j.ejmg.2019.03.001;
RA   Gumus E.;
RT   "Extending the phenotype of Xia-Gibbs syndrome in a two-year-old patient
RT   with craniosynostosis with a novel de novo AHDC1 missense mutation.";
RL   Eur. J. Med. Genet. 63:103637-103637(2020).
RN   [24]
RP   VARIANT XIGIS 151-ARG--LEU-1603 DEL.
RX   PubMed=32256298; DOI=10.1159/000505843;
RA   Cardoso-Dos-Santos A.C., Oliveira Silva T., Silveira Faccini A.,
RA   Woycinck Kowalski T., Bertoli-Avella A., Morales Saute J.A.,
RA   Schuler-Faccini L., de Oliveira Poswar F.;
RT   "Novel AHDC1 gene mutation in a brazilian individual: implications of Xia-
RT   Gibbs syndrome.";
RL   Mol. Syndromol. 11:24-29(2020).
RN   [25]
RP   VARIANT XIGIS 823-SER--LEU-1603 DEL.
RX   PubMed=34229113; DOI=10.1016/j.ejmg.2021.104280;
RA   Faergeman S.L., Bojesen A.B., Rasmussen M., Becher N., Andreasen L.,
RA   Andersen B.N., Erbs E., Lildballe D.L., Nielsen J.E.K., Zilmer M.,
RA   Hammer T.B., Andersen M.O., Brasch-Andersen C., Fagerberg C.R., Illum N.O.,
RA   Thorup M.B., Gregersen P.A.;
RT   "Phenotypic heterogeneity and mosaicism in Xia-Gibbs syndrome: Five Danish
RT   patients with novel variants in AHDC1.";
RL   Eur. J. Med. Genet. 64:104280-104280(2021).
RN   [26]
RP   VARIANTS XIGIS SER-47; TRP-487; ASP-537; SER-548; HIS-549; PRO-1348 AND
RP   SER-1478.
RX   PubMed=34950897; DOI=10.1016/j.xhgg.2021.100049;
RA   Khayat M.M., Hu J., Jiang Y., Li H., Chander V., Dawood M., Hansen A.W.,
RA   Li S., Friedman J., Cross L., Bijlsma E.K., Ruivenkamp C.A.L.,
RA   Sansbury F.H., Innis J.W., O'Shea J.O., Meng Q., Rosenfeld J.A.,
RA   McWalter K., Wangler M.F., Lupski J.R., Posey J.E., Murdock D., Gibbs R.A.;
RT   "AHDC1 missense mutations in Xia-Gibbs syndrome.";
RL   HGG Adv. 2:0-0(2021).
RN   [27]
RP   VARIANTS XIGIS 262-GLN--LEU-1603 DEL; 327-GLN--LEU-1603 DEL;
RP   587-ARG--LEU-1603 DEL; ASN-607; 688-ARG--LEU-1603 DEL; 730-GLU--LEU-1603
RP   DEL; ARG-792; 825-GLN--LEU-1603 DEL; 882-GLN--LEU-1603 DEL;
RP   925-ARG--LEU-1603 DEL; 970-GLN--LEU-1603 DEL; 978-GLN--LEU-1603 DEL;
RP   1068-TYR--LEU-1603 DEL; 1156-GLN--LEU-1603 DEL; 1258-SER--LEU-1603 DEL AND
RP   1330-SER--LEU-1603 DEL, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF
RP   VARIANTS XIGIS 262-GLN--LEU-1603 DEL; ASN-607; ARG-792; 925-ARG--LEU-1603
RP   DEL AND 970-GLN--LEU-1603 DEL.
RX   PubMed=33644933; DOI=10.1002/humu.24190;
RA   Khayat M.M., Li H., Chander V., Hu J., Hansen A.W., Li S., Traynelis J.,
RA   Shen H., Weissenberger G., Stossi F., Johnson H.L., Lupski J.R.,
RA   Posey J.E., Sabo A., Meng Q., Murdock D.R., Wangler M., Gibbs R.A.;
RT   "Phenotypic and protein localization heterogeneity associated with AHDC1
RT   pathogenic protein-truncating alleles in Xia-Gibbs syndrome.";
RL   Hum. Mutat. 42:577-591(2021).
RN   [28]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=35585237; DOI=10.1038/s41586-022-04727-9;
RA   Collier A., Liu A., Torkelson J., Pattison J., Gaddam S., Zhen H.,
RA   Patel T., McCarthy K., Ghanim H., Oro A.E.;
RT   "Gibbin mesodermal regulation patterns epithelial development.";
RL   Nature 0:0-0(2022).
CC   -!- FUNCTION: Transcription factor required for the proper patterning of
CC       the epidermis, which plays a key role in early epithelial morphogenesis
CC       (PubMed:35585237). Directly binds promoter and enhancer regions and
CC       acts by maintaining local enhancer-promoter chromatin architecture
CC       (PubMed:35585237). Interacts with many sequence-specific zinc-finger
CC       transcription factors and methyl-CpG-binding proteins to regulate the
CC       expression of mesoderm genes that wire surface ectoderm stratification
CC       (PubMed:35585237). {ECO:0000269|PubMed:35585237}.
CC   -!- INTERACTION:
CC       Q5TGY3; P54253: ATXN1; NbExp=5; IntAct=EBI-948813, EBI-930964;
CC       Q5TGY3; P42858: HTT; NbExp=12; IntAct=EBI-948813, EBI-466029;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:33644933}. Chromosome
CC       {ECO:0000269|PubMed:35585237}. Note=Associates with promoter and
CC       enhancer regions. {ECO:0000269|PubMed:35585237}.
CC   -!- DISEASE: Xia-Gibbs syndrome (XIGIS) [MIM:615829]: An autosomal dominant
CC       disorder characterized by intellectual disability, mild dysmorphism,
CC       hypotonia, delayed psychomotor development with absent or poor
CC       expressive language, hypoplasia of the corpus callosum, simplified
CC       gyral pattern, and delayed myelination. {ECO:0000269|PubMed:24791903,
CC       ECO:0000269|PubMed:27148574, ECO:0000269|PubMed:29230160,
CC       ECO:0000269|PubMed:29696776, ECO:0000269|PubMed:30152016,
CC       ECO:0000269|PubMed:30622101, ECO:0000269|PubMed:30729726,
CC       ECO:0000269|PubMed:30858058, ECO:0000269|PubMed:31182893,
CC       ECO:0000269|PubMed:32256298, ECO:0000269|PubMed:33644933,
CC       ECO:0000269|PubMed:34229113, ECO:0000269|PubMed:34950897}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB50205.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAC86163.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL031729; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AK125431; BAC86163.1; ALT_INIT; mRNA.
DR   EMBL; BC002677; AAH02677.2; -; mRNA.
DR   EMBL; BC014394; AAH14394.3; -; mRNA.
DR   EMBL; U79259; AAB50205.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS30652.1; -.
DR   RefSeq; NP_001025053.1; NM_001029882.3.
DR   RefSeq; XP_005245905.1; XM_005245848.3.
DR   RefSeq; XP_005245906.1; XM_005245849.3.
DR   RefSeq; XP_005245907.1; XM_005245850.3.
DR   RefSeq; XP_005245908.1; XM_005245851.3.
DR   RefSeq; XP_005245909.1; XM_005245852.3.
DR   RefSeq; XP_011539557.1; XM_011541255.1.
DR   RefSeq; XP_011539558.1; XM_011541256.2.
DR   RefSeq; XP_011539559.1; XM_011541257.2.
DR   AlphaFoldDB; Q5TGY3; -.
DR   BioGRID; 118093; 65.
DR   IntAct; Q5TGY3; 24.
DR   MINT; Q5TGY3; -.
DR   STRING; 9606.ENSP00000363123; -.
DR   GlyCosmos; Q5TGY3; 2 sites, 1 glycan.
DR   GlyGen; Q5TGY3; 8 sites, 1 O-linked glycan (8 sites).
DR   iPTMnet; Q5TGY3; -.
DR   PhosphoSitePlus; Q5TGY3; -.
DR   BioMuta; AHDC1; -.
DR   DMDM; 74746532; -.
DR   EPD; Q5TGY3; -.
DR   jPOST; Q5TGY3; -.
DR   MassIVE; Q5TGY3; -.
DR   MaxQB; Q5TGY3; -.
DR   PaxDb; Q5TGY3; -.
DR   PeptideAtlas; Q5TGY3; -.
DR   ProteomicsDB; 65133; -.
DR   Antibodypedia; 30793; 20 antibodies from 9 providers.
DR   DNASU; 27245; -.
DR   Ensembl; ENST00000247087.10; ENSP00000247087.4; ENSG00000126705.15.
DR   Ensembl; ENST00000374011.6; ENSP00000363123.2; ENSG00000126705.15.
DR   Ensembl; ENST00000642245.1; ENSP00000495072.1; ENSG00000126705.15.
DR   Ensembl; ENST00000642416.1; ENSP00000494394.1; ENSG00000126705.15.
DR   Ensembl; ENST00000644989.1; ENSP00000495665.1; ENSG00000126705.15.
DR   Ensembl; ENST00000673934.1; ENSP00000501218.1; ENSG00000126705.15.
DR   GeneID; 27245; -.
DR   KEGG; hsa:27245; -.
DR   MANE-Select; ENST00000673934.1; ENSP00000501218.1; NM_001371928.1; NP_001358857.1.
DR   UCSC; uc009vsy.4; human.
DR   AGR; HGNC:25230; -.
DR   CTD; 27245; -.
DR   DisGeNET; 27245; -.
DR   GeneCards; AHDC1; -.
DR   GeneReviews; AHDC1; -.
DR   HGNC; HGNC:25230; AHDC1.
DR   HPA; ENSG00000126705; Low tissue specificity.
DR   MalaCards; AHDC1; -.
DR   MIM; 615790; gene.
DR   MIM; 615829; phenotype.
DR   neXtProt; NX_Q5TGY3; -.
DR   OpenTargets; ENSG00000126705; -.
DR   Orphanet; 412069; AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome.
DR   PharmGKB; PA142672633; -.
DR   VEuPathDB; HostDB:ENSG00000126705; -.
DR   eggNOG; ENOG502QSFA; Eukaryota.
DR   GeneTree; ENSGT00390000018883; -.
DR   HOGENOM; CLU_004578_0_0_1; -.
DR   InParanoid; Q5TGY3; -.
DR   OMA; TEWAGDK; -.
DR   OrthoDB; 4640697at2759; -.
DR   PhylomeDB; Q5TGY3; -.
DR   TreeFam; TF332128; -.
DR   PathwayCommons; Q5TGY3; -.
DR   SignaLink; Q5TGY3; -.
DR   SIGNOR; Q5TGY3; -.
DR   BioGRID-ORCS; 27245; 16 hits in 1152 CRISPR screens.
DR   ChiTaRS; AHDC1; human.
DR   GenomeRNAi; 27245; -.
DR   Pharos; Q5TGY3; Tdark.
DR   PRO; PR:Q5TGY3; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q5TGY3; protein.
DR   Bgee; ENSG00000126705; Expressed in paraflocculus and 149 other tissues.
DR   Genevisible; Q5TGY3; HS.
DR   GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0140585; F:promoter-enhancer loop anchoring activity; IDA:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0001707; P:mesoderm formation; IDA:UniProtKB.
DR   GO; GO:0043589; P:skin morphogenesis; IDA:UniProtKB.
DR   InterPro; IPR039225; AHDC1.
DR   InterPro; IPR032757; DUF4683.
DR   PANTHER; PTHR15617:SF1; AT-HOOK DNA-BINDING MOTIF-CONTAINING PROTEIN 1; 1.
DR   PANTHER; PTHR15617; UNCHARACTERIZED; 1.
DR   Pfam; PF15735; DUF4683; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Chromosome; Developmental protein; Differentiation;
KW   Disease variant; DNA-binding; Intellectual disability; Isopeptide bond;
KW   Methylation; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..1603
FT                   /note="Transcription factor Gibbin"
FT                   /id="PRO_0000313824"
FT   DNA_BIND        396..408
FT                   /note="A.T hook 1"
FT   DNA_BIND        544..556
FT                   /note="A.T hook 2"
FT   REGION          19..108
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          150..236
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          264..285
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          394..467
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          581..607
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          717..792
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          806..827
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1159..1198
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1253..1286
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1503..1533
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        26..47
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        61..75
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        165..179
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        182..202
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        424..448
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        721..737
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        808..827
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1159..1177
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         79
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PAL7"
FT   MOD_RES         268
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         596
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         829
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         846
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         891
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         896
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1064
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1187
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1322
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PAL7"
FT   MOD_RES         1324
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PAL7"
FT   MOD_RES         1399
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1401
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PAL7"
FT   MOD_RES         1403
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PAL7"
FT   MOD_RES         1507
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1549
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PAL7"
FT   CROSSLNK        609
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1409
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VARIANT         47
FT                   /note="P -> S (in XIGIS; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:34950897"
FT                   /id="VAR_086657"
FT   VARIANT         151..1603
FT                   /note="Missing (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:32256298"
FT                   /id="VAR_086658"
FT   VARIANT         262..1603
FT                   /note="Missing (in XIGIS; impaired nuclear localization)"
FT                   /evidence="ECO:0000269|PubMed:29696776,
FT                   ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086659"
FT   VARIANT         327..1603
FT                   /note="Missing (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:30622101,
FT                   ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086660"
FT   VARIANT         487
FT                   /note="R -> W (in XIGIS; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:34950897"
FT                   /id="VAR_086661"
FT   VARIANT         494..1603
FT                   /note="Missing (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:27148574,
FT                   ECO:0000269|PubMed:30152016"
FT                   /id="VAR_086662"
FT   VARIANT         537
FT                   /note="G -> D (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:34950897"
FT                   /id="VAR_086663"
FT   VARIANT         548
FT                   /note="G -> S (in XIGIS; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:34950897"
FT                   /id="VAR_086664"
FT   VARIANT         549
FT                   /note="R -> H (in XIGIS; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:34950897"
FT                   /id="VAR_086665"
FT   VARIANT         587..1603
FT                   /note="Missing (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:30152016,
FT                   ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086666"
FT   VARIANT         607
FT                   /note="D -> N (in XIGIS; unknown pathological significance;
FT                   does not affect nuclear localization)"
FT                   /evidence="ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086667"
FT   VARIANT         688..1603
FT                   /note="Missing (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:29696776,
FT                   ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086668"
FT   VARIANT         730..1603
FT                   /note="Missing (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086669"
FT   VARIANT         792
FT                   /note="G -> R (in XIGIS; unknown pathological significance;
FT                   does not affect nuclear localization)"
FT                   /evidence="ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086670"
FT   VARIANT         823..1603
FT                   /note="Missing (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:34229113"
FT                   /id="VAR_086671"
FT   VARIANT         825..1603
FT                   /note="Missing (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:30152016,
FT                   ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086672"
FT   VARIANT         882..1603
FT                   /note="Missing (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:29696776,
FT                   ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086673"
FT   VARIANT         925..1603
FT                   /note="Missing (in XIGIS; does not affect nuclear
FT                   localization)"
FT                   /evidence="ECO:0000269|PubMed:29696776,
FT                   ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086674"
FT   VARIANT         935
FT                   /note="A -> T (in dbSNP:rs4908364)"
FT                   /evidence="ECO:0000269|PubMed:14702039"
FT                   /id="VAR_037765"
FT   VARIANT         970..1603
FT                   /note="Missing (in XIGIS; does not affect nuclear
FT                   localization)"
FT                   /evidence="ECO:0000269|PubMed:29696776,
FT                   ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086675"
FT   VARIANT         978..1603
FT                   /note="Missing (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086676"
FT   VARIANT         1068..1603
FT                   /note="Missing (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086677"
FT   VARIANT         1156..1603
FT                   /note="Missing (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086678"
FT   VARIANT         1258..1603
FT                   /note="Missing (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:29696776,
FT                   ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086679"
FT   VARIANT         1330..1603
FT                   /note="Missing (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:29696776,
FT                   ECO:0000269|PubMed:33644933"
FT                   /id="VAR_086680"
FT   VARIANT         1348
FT                   /note="S -> P (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:34950897"
FT                   /id="VAR_086681"
FT   VARIANT         1457
FT                   /note="D -> G (in XIGIS)"
FT                   /evidence="ECO:0000269|PubMed:30858058"
FT                   /id="VAR_086682"
FT   VARIANT         1478
FT                   /note="P -> S (in XIGIS; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:34950897"
FT                   /id="VAR_086683"
FT   CONFLICT        1453
FT                   /note="Q -> H (in Ref. 4; AAB50205)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1603 AA;  168349 MW;  2BAC8DC14836F493 CRC64;
     MRVKPQGLVV TSSAVCSSPD YLREPKYYPG GPPTPRPLLP TRPPASPPDK AFSTHAFSEN
     PRPPPRRDPS TRRPPVLAKG DDPLPPRAAR PVSQARCPTP VGDGSSSRRC WDNGRVNLRP
     VVQLIDIMKD LTRLSQDLQH SGVHLDCGGL RLSRPPAPPP GDLQYSFFSS PSLANSIRSP
     EERATPHAKS ERPSHPLYEP EPEPRDSPQP GQGHSPGATA AATGLPPEPE PDSTDYSELA
     DADILSELAS LTCPEAQLLE AQALEPPSPE PEPQLLDPQP RFLDPQALEP LGEALELPPL
     QPLADPLGLP GLALQALDTL PDSLESQLLD PQALDPLPKL LDVPGRRLEP QQPLGHCPLA
     EPLRLDLCSP HGPPGPEGHP KYALRRTDRP KILCRRRKAG RGRKADAGPE GRLLPLPMPT
     GLVAALAEPP PPPPPPPPAL PGPGPVSVPE LKPESSQTPV VSTRKGKCRG VRRMVVKMAK
     IPVSLGRRNK TTYKVSSLSS SLSVEGKELG LRVSAEPTPL LKMKNNGRNV VVVFPPGEMP
     IILKRKRGRP PKNLLLGPGK PKEPAVVAAE AATVAAATMA MPEVKKRRRR KQKLASPQPS
     YAADANDSKA EYSDVLAKLA FLNRQSQCAG RCSPPRCWTP SEPESVHQAP DTQSISHFLH
     RVQGFRRRGG KAGGFGGRGG GHAAKSARCS FSDFFEGIGK KKKVVAVAAA GVGGPGLTEL
     GHPRKRGRGE VDAVTGKPKR KRRSRKNGTL FPEQVPSGPG FGEAGAEWAG DKGGGWAPHH
     GHPGGQAGRN CGFQGTEARA FASTGLESGA SGRGSYYSTG APSGQTELSQ ERQNLFTGYF
     RSLLDSDDSS DLLDFALSAS RPESRKASGT YAGPPTSALP AQRGLATFPS RGAKASPVAV
     GSSGAGADPS FQPVLSARQT FPPGRAASYG LTPAASDCRA AETFPKLVPP PSAMARSPTT
     HPPANTYLPQ YGGYGAGQSV FAPTKPFTGQ DCANSKDCSF AYGSGNSLPA SPSSAHSAGY
     APPPTGGPCL PPSKASFFSS SEGAPFSGSA PTPLRCDSRA STVSPGGYMV PKGTTASATS
     AASAASSSSS SFQPSPENCR QFAGASQWPF RQGYGGLDWA SEAFSQLYNP SFDCHVSEPN
     VILDISNYTP QKVKQQTAVS ETFSESSSDS TQFNQPVGGG GFRRANSEAS SSEGQSSLSS
     LEKLMMDWNE ASSAPGYNWN QSVLFQSSSK PGRGRRKKVD LFEASHLGFP TSASAAASGY
     PSKRSTGPRQ PRGGRGGGAC SAKKERGGAA AKAKFIPKPQ PVNPLFQDSP DLGLDYYSGD
     SSMSPLPSQS RAFGVGERDP CDFIGPYSMN PSTPSDGTFG QGFHCDSPSL GAPELDGKHF
     PPLAHPPTVF DAGLQKAYSP TCSPTLGFKE ELRPPPTKLA ACEPLKHGLQ GASLGHAAAA
     QAHLSCRDLP LGQPHYDSPS CKGTAYWYPP GSAARSPPYE GKVGTGLLAD FLGRTEAACL
     SAPHLASPPA TPKADKEPLE MARPPGPPRG PAAAAAGYGC PLLSDLTLSP VPRDSLLPLQ
     DTAYRYPGFM PQAHPGLGGG PKSGFLGPMA EPHPEDTFTV TSL
//
